Related Experiment Video
Updated: Sep 13, 2025
09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.3K
Alzheimer's Disease: Treatment Challenges for the Future
John Hardy1,2
1Department of Neurodegenerative Disease, UCL Institute of Neurology, United Kingdom.
Journal of Neurochemistry
|July 31, 2025
Summary
The first anti-amyloid antibodies for Alzheimer's disease, lecanemab and donanemab, represent a significant advancement. Future research will focus on improving these therapies and understanding Alzheimer's disease pathogenesis.
Area of Science:
- Neurology
- Immunotherapy
- Neurodegenerative Diseases
Background:
- Alzheimer's disease is a prevalent neurodegenerative disorder with limited effective treatments.
- Recent approvals of anti-amyloid antibodies mark a significant shift in therapeutic strategies.
- Lecanemab and donanemab are the first disease-modifying therapies targeting amyloid pathology.
Purpose of the Study:
- To review the implications of new anti-amyloid antibody therapies for Alzheimer's disease pathogenesis.
- To discuss the future directions for developing safer and more effective Alzheimer's disease treatments.
- To highlight the need for continued research in drug development, biomarkers, and neuropathology.
Main Methods:
- Review of current literature on anti-amyloid antibody treatments for Alzheimer's disease.
- Analysis of the impact of lecanemab and donanemab on disease understanding and clinical practice.
- Discussion of future research priorities in Alzheimer's disease therapeutics.
Main Results:
- The introduction of lecanemab and donanemab signifies a new era in Alzheimer's disease treatment.
- These therapies offer insights into amyloid's role in disease pathogenesis.
- Current therapies are imperfect, necessitating further advancements.
Conclusions:
- Anti-amyloid antibodies represent a breakthrough in Alzheimer's disease treatment and pathogenesis research.
- Future research should prioritize reducing side effects, early patient identification via biomarkers, and understanding treatment mechanisms.
- The goal is to achieve safe, effective, and disease-halting therapies for Alzheimer's disease.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:30Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
01:15Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
01:24Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
01:28Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100